Key Takeaways
- Do not wait for an arbitrary deadline when age, irregular or absent periods, known tubal or uterine disease, endometriosis, previous gonadotoxic treatment, sexual dysfunction or suspected male-factor infertility already makes delay important.[1][2]
- When sperm and eggs from two partners are involved, investigate both at the same time. A fertility assessment is not a sequence in which one person must complete every test before the other is examined.[2][3]
- A useful core work-up asks three questions: Is ovulation occurring? Are the uterus and tubes suitable for the intended route to pregnancy? Is sperm production and delivery adequate? The exact tests depend on history and planned treatment.
- AMH and antral follicle count mainly help estimate ovarian response to stimulation. They are not egg-quality tests and should not be used alone to declare that someone is fertile or infertile.[2]
- One abnormal semen analysis is a finding to confirm and interpret, not a complete diagnosis. Collection conditions, illness, abstinence interval, transport and laboratory method all matter.[3][4]
- Decline a large “fertility panel” unless the clinician can say how each result would alter management. Routine laparoscopy, postcoital testing, endometrial biopsy, immune or thrombophilia panels, karyotyping and sperm DNA-fragmentation testing are not part of every initial evaluation.[2][3]
Content
A good fertility assessment is deliberately small at the beginning. It uses history, examination and a limited set of high-yield tests to locate the decision: continue trying, correct a medical problem, investigate one system further, use ovulation induction or insemination, move to IVF, preserve fertility, or seek genetic counselling. It expands only when an initial finding or the intended treatment creates a reason.
WHO notes that infertility may result from male, female or unexplained factors.[1] “Unexplained” should mean that an appropriate basic evaluation did not identify a cause; it should not mean that one partner was never assessed or that a standard test was missing.
Know when the clock starts—and when it should not control the decision
For couples trying through regular unprotected intercourse, evaluation commonly begins after 12 months when the egg-providing partner is younger than 35 and after six months at age 35 or older. More immediate assessment may be appropriate over age 40.[2][5]
Do not wait for those milestones when there is:
- no menstrual period, markedly irregular cycles or repeated bleeding between periods;
- known or suspected endometriosis, tubal disease, uterine abnormality or prior pelvic infection;
- previous ectopic pregnancy, pelvic surgery or ovarian surgery;
- chemotherapy, pelvic radiation or another fertility-threatening treatment;
- known genetic risk or a need for fertility preservation;
- erectile, ejaculatory or sexual-function difficulty;
- previous testicular injury, undescended testis, genital surgery or suspected sperm problem; or
- recurrent pregnancy loss, which requires a question-specific pathway rather than simply repeating a generic infertility panel.
People using donor sperm, reciprocal IVF or other routes do not need to “try for 12 months” to justify evaluation. The work-up should be tailored to the planned route and to the person who will provide eggs, sperm or carry the pregnancy.[2]
Start with a chronology, not a bag of laboratory reports
Before the first China appointment, prepare a one-page reproductive timeline. Record when attempts began, frequency and method of exposure to sperm, pregnancies and outcomes, cycle length and variation, pelvic or testicular symptoms, infections, surgery, contraception history and every prior treatment. Include dates and doses of fertility medicines, follicles seen, eggs retrieved, fertilisation and embryo outcomes—not just “IVF failed.”
List all medicines and supplements. Testosterone and anabolic steroids can suppress sperm production; some cancer, psychiatric and other treatments can affect reproductive function. Do not stop prescribed medicine without the responsible clinician, but make exposure visible.
Bring original reports in the source language plus translations. For ultrasound and hysterosalpingography, obtain the images as well as the report. For semen analysis, retain collection instructions, collection time, abstinence interval, whether the whole sample was captured, time to analysis and the laboratory's reference information. A translated summary without methods is often impossible to compare.
Assess the egg-providing and pregnancy-carrying patient by clinical question
The initial visit should cover age, menstrual and ovulation pattern, pregnancy history, pelvic pain, abnormal bleeding, infection, surgery, family history, endocrine symptoms and physical findings. The tests then follow the question.
Ovulation. A reliably regular menstrual history may already support an ovulatory pattern. When cycles are irregular or absent, testing should look for the cause rather than repeatedly ordering a “day 21 progesterone” without adjusting for cycle length. Thyroid testing is useful when thyroid disease could impair fertility; prolactin is not a universal screen but is indicated with galactorrhoea, oligomenorrhoea or amenorrhoea.[2]
Ovarian reserve. AMH can be measured on many cycle days; antral follicle count uses transvaginal ultrasound; early-follicular FSH and estradiol may sometimes add context. These tests estimate the likely quantity of response to stimulation better than they predict natural conception. Age remains a major predictor of reproductive potential and egg-related chromosome risk. A low AMH does not prove zero chance of unassisted pregnancy, and a high AMH does not guarantee healthy eggs or a live birth.[2][6]
Uterus and ovaries. Transvaginal ultrasound can identify fibroids, adenomyosis, ovarian cysts or other anatomy. If a cavity abnormality is suspected, saline-infusion sonography or hysteroscopy may be considered. Hysteroscopy gives direct assessment and can treat selected intrauterine lesions, but it is not an automatic first test for everyone.[2]
Tubal patency. Hysterosalpingography or an ultrasound-based contrast test may be used when open tubes matter to natural conception or insemination. The report should name each tube, spill and any hydrosalpinx. Tubal testing may be unnecessary before a pathway that bypasses the tubes, unless a tubal lesion would itself affect treatment. Diagnostic laparoscopy is not routine without symptoms, abnormal imaging or another specific indication.[2]
Assess sperm production and delivery in parallel
The AUA/ASRM guideline says the initial male evaluation should include reproductive history and one or more semen analyses, and that both partners should be assessed concurrently.[3] The history should include puberty, paternity, genital infections and surgery, undescended testes, torsion or trauma, cancer treatment, fever, medicines, testosterone or steroid use, occupational heat or toxin exposure, sexual function and family history.
A semen analysis is more than a sperm count. It typically describes volume, concentration, total number, motility and morphology, with other findings where relevant. WHO's sixth-edition laboratory manual exists to improve standardisation and comparability between laboratories.[4] Reference limits are not a cliff between “fertile” and “infertile”; results overlap, vary biologically and must be read with the couple's history.
If a result is abnormal, ask whether and when it should be repeated under controlled collection conditions. A recent high fever or incomplete collection can distort interpretation. Persistent abnormalities, azoospermia, very low concentration, examination findings or endocrine symptoms may prompt assessment by a male-reproductive specialist, hormone testing, genetic testing or targeted imaging. The indication should be written. Routine scrotal or transrectal ultrasound and routine sperm DNA-fragmentation testing are not first-line tests for every patient.[3]
Separate core tests from conditional tests
The most useful question at the consultation is: What decision changes if this result is normal, abnormal or inconclusive? If no answer exists, the test may be premature.
Conditional investigations can be valuable when the history supports them:
- genetic carrier testing or karyotype for a defined family history, recurrent loss, ovarian insufficiency, azoospermia or severe sperm abnormality;
- androgen, 17-hydroxyprogesterone or metabolic assessment with signs of hyperandrogenism or PCOS;
- prolactin with galactorrhoea or ovulatory disturbance;
- targeted infection testing based on symptoms, exposure and treatment requirements;
- pelvic MRI for a defined anatomical or endometriosis question; and
- hysteroscopy or laparoscopy when imaging, symptoms or a planned intervention supplies an indication.
By contrast, ASRM lists laparoscopy for unexplained infertility, advanced sperm-function testing, postcoital testing, thrombophilia testing, immune testing, routine karyotype, endometrial biopsy and routine prolactin among tests that should not be ordered for every initial evaluation without a specific indication.[2] The 2026 NICE guideline also recommends against routine sperm DNA-integrity testing and postcoital cervical-mucus testing.[7] A clinic should not rebrand low-evidence add-ons as a mandatory “international patient package.”
Use a staged timetable rather than promising a one-day diagnosis
Many first-line elements can be organised in one visit, but a complete answer may cross cycles or require repeat samples.
Before travel: obtain a clinician's record review; confirm which existing tests are acceptable; note cycle day, expiry window and laboratory method; book a reproductive-medicine appointment and, if indicated, male-reproductive assessment on compatible dates.
First clinical contact: complete both histories, examination as appropriate, medication review, pregnancy testing when relevant and a preliminary problem list. The clinician should identify what can already be concluded and what remains uncertain.
Cycle-dependent window: early-cycle ultrasound and selected hormones may require particular timing. Tubal or cavity testing is scheduled to avoid an existing pregnancy and according to the centre's infection and cycle protocol. “Day 2” or “day 21” should never be applied without defining day 1 and the person's actual cycle length.
Semen testing: follow the receiving laboratory's written abstinence and collection instructions. If collection is off-site, confirm permitted transport time and temperature. Do not carry a sample across an international border without explicit legal and laboratory approval.
Review visit: results should be discussed together, not released as unrelated red and green flags. Ask for a working diagnosis, degree of confidence, missing information, options and a ranked next step.
Targeted second stage: repeat or specialist tests should be triggered by a finding. ESHRE notes that evidence for many additional tests in unexplained infertility is limited or very low quality.[8]
Decide which tests from home can safely be reused
Repeating every test wastes time and money; accepting every outside result without scrutiny can also be unsafe. Before travel, ask the Chinese clinician to mark each result as accepted, accepted if still within a stated date window, requires images or methods, or must be repeated.
Check:
- patient name, date of birth and passport-name match;
- specimen or examination date and cycle day;
- units and reference interval;
- assay platform when serial comparison matters, especially AMH;
- complete ultrasound or HSG images, measurements and laterality;
- semen collection and processing method;
- whether infection tests meet the treatment laboratory's regulatory window; and
- whether a translated report preserves numbers, symbols and qualifiers.
An unexplained difference between two AMH or semen results should trigger a method and timing review before it is labelled rapid biological decline.
Verify the service when assessment may lead to assisted reproduction
Some diagnostic work can occur in a general gynaecology, urology or andrology service. If the plan may proceed to insemination, IVF, ICSI or PGT, verify the exact institution and approved technology. China's National Health Commission maintains information on approved human assisted-reproduction institutions, while provincial authorities oversee planning, approval and supervision.[9][10]
Ask whether the assessment is performed by the same team that would deliver treatment, whether outside results enter the formal medical record, and whether a new consultation is required before treatment. A coordinator can arrange dates and translations but should not interpret ovarian reserve, semen quality or genetic risk.
Leave with a diagnostic map, even if there is no final diagnosis
The written output should contain:
- duration and route of trying to conceive;
- reproductive diagnosis for each partner or participant;
- evidence about ovulation, ovarian reserve, uterine cavity, tubes and semen;
- which findings are confirmed, borderline, inconsistent or still missing;
- age- and diagnosis-related urgency without a guaranteed prognosis;
- next option and its clinical objective;
- alternatives and the consequence of waiting;
- additional tests, each linked to a decision; and
- who reviews results and provides follow-up after return home.
If the conclusion is “unexplained infertility,” confirm which basic domains were actually evaluated. If the conclusion is diminished ovarian reserve, ask what it predicts—usually stimulation response more than natural fertility—and what action changes now. If semen is abnormal, ensure the male patient receives appropriate clinical assessment rather than being reduced to an instruction to use ICSI.
Medical disclaimer: This article provides general education, not an individual fertility diagnosis or test order. Test selection and timing depend on age, anatomy, symptoms, pregnancy goals and the intended treatment. Seek urgent local care for severe pelvic or testicular pain, heavy bleeding, fainting or suspected ectopic pregnancy.
FAQ
How long should an international patient stay in China for a fertility assessment?
There is no reliable universal duration. History, ultrasound, blood tests and semen analysis may fit into a short visit, but cycle-timed imaging, repeat semen testing, genetic results or specialist review can take longer. Obtain a personalised test calendar before booking non-refundable travel.
Is AMH a test of egg quality or the chance of natural pregnancy?
No. AMH mainly helps estimate ovarian response and possible egg yield during stimulation. It must be interpreted with age, antral follicle count, history and treatment goal; it does not directly measure egg quality and is a poor stand-alone predictor of natural conception.[2][6]
Does one abnormal semen result mean male infertility is confirmed?
Not by itself. Semen parameters vary, and collection, fever, abstinence, transport and laboratory methods affect results. The clinician may repeat the analysis and should arrange a male-reproductive evaluation when abnormalities persist or are severe.[3][4]
Do I need hysteroscopy and laparoscopy as part of the first work-up?
Usually not routinely. Ultrasound and a tubal-patency test often answer the first anatomical questions. Hysteroscopy or laparoscopy is reserved for a suspected cavity, tubal, endometriosis or pelvic problem, or when an intervention is planned.[2]
Why does the Chinese clinic want to repeat tests already done at home?
A repeat can be justified by expiry, cycle timing, incompatible methods, missing images, identity or regulatory requirements, or a result that needs confirmation. Ask the clinician to document the reason for each repeat; “part of the package” is not a clinical explanation.
Sources
- World Health Organization — Infertility Fact Sheet
- American Society for Reproductive Medicine — Fertility Evaluation of Infertile Women: A Committee Opinion (2021)
- American Urological Association and American Society for Reproductive Medicine — Diagnosis and Treatment of Infertility in Men, Guideline Part I
- World Health Organization — Laboratory Manual for the Examination and Processing of Human Semen, 6th Edition
- American College of Obstetricians and Gynecologists — Evaluating Infertility
- American Society for Reproductive Medicine — Testing and Interpreting Measures of Ovarian Reserve
- National Institute for Health and Care Excellence — Fertility Problems: Investigation and Management Strategies (NG257, 2026)
- European Society of Human Reproduction and Embryology — Evidence-Based Guideline on Unexplained Infertility
- National Health Commission of China — Approved Human Assisted Reproductive Technology Institutions
- National Health Commission of China — Guiding Principles for Planning the Application of Human Assisted Reproductive Technology (2021)
Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Editorial note: The image shows a reproductive-medicine consultation focused on sperm, egg and fertilisation, with an international couple and a recognisably Chinese city context. It supports assessment and counselling without showing test results, a named clinic or a promised outcome.